Cargando…
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial
IMPORTANCE: Anthracycline-based therapy is standard first-line treatment for most patients with advanced and metastatic sarcomas. Although multiple trials have attempted to show improved outcomes in patients with soft-tissue sarcoma over doxorubicin monotherapy, each has fallen short of demonstratin...
Autores principales: | Pollack, Seth M., Redman, Mary W., Baker, Kelsey K., Wagner, Michael J., Schroeder, Brett A., Loggers, Elizabeth T., Trieselmann, Kathryn, Copeland, Vanessa C., Zhang, Shihong, Black, Graeme, McDonnell, Sabrina, Gregory, Jeffrey, Johnson, Rylee, Moore, Roxanne, Jones, Robin L., Cranmer, Lee D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489365/ https://www.ncbi.nlm.nih.gov/pubmed/32910151 http://dx.doi.org/10.1001/jamaoncol.2020.3689 |
Ejemplares similares
-
Doxorubicin and Aclarubicin: Shuffling Anthracycline
Glycans for Improved Anticancer Agents
por: Wander, Dennis P. A., et al.
Publicado: (2020) -
Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial
por: Seo, Yongwoo David, et al.
Publicado: (2023) -
Pazopanib in the management of advanced soft tissue sarcomas
por: Cranmer, Lee D, et al.
Publicado: (2016) -
Propranolol for the treatment of vascular sarcomas
por: Wagner, Michael J, et al.
Publicado: (2018) -
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
por: Rafiyath, Shamudheen M, et al.
Publicado: (2012)